VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 15, 2007) - Upstream Biosciences Inc. (OTCBB: UPBS) today announced that the Ministry of Health of Uganda has issued a letter of intent confirming its plans to collaborate with Upstream on the development of the company’s novel therapeutic compounds to treat topical parasitic diseases, focusing initially on African sleeping sickness and leishmaniasis. These parasites, which belong to a family of protozoa species that include Chagas disease and malaria, infect millions of individuals annually.
